Renin Inhibitor Market Trends

  • Report ID: 2633
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Renin Inhibitor Market Trends

Growth Drivers

Frequency of Cardiovascular Diseases Among the Geriatric Population

The renin inhibitor market is estimated to observe a significant growth on account of the frequency of cardiovascular diseases among the geriatric population as aged individuals continue to become prone to hypertension and other cardiovascular complications. Additionally, an individual who suffers from hypertension is very susceptible to other complications such as aneurysm and heart failure. Thus, requires early diagnosis as well as management by using renin inhibitor drugs.

Rampant Research and Development for the Antihypertensive Drugs Driving the Global Market

An upsurge in research related to antihypertensive drugs in developing economies coupled with pulmonary hypertensive practices offering training programs for people, a high predominance of incessant illness, initiatives are taken by the government and the growing commonness of hypertension in youth population in emerging economies are anticipated to fuel the growth of renin inhibitor over the forecast period., i.e. 2020-2028.

Challenges

Side Effects of Renin Inhibitors

Growth of renin inhibitor is expected to be hampered by the side effects of drugs such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization coupled with recent patent expirations.

Renin Inhibitor Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2633
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Renin Inhibitor Market size is likely to expand at more than 6.6% CAGR during the forecast period i.e., between 2024-2036.

Renin Inhibitor Market size is likely to expand at more than 6.6% CAGR during the forecast period i.e., between 2024-2036.

North America industry is set to account for largest revenue share by 2036, on account of a rise in the prevalence of hypertension and chronic kidney disorders.

The major players in the market are Johnson & Johnson, Pfizer, Bio-Rad Laboratories Inc., Sanofi, Lupin, Merck & Co., Astra Zeneca, Daiichi Sankyo, Novartis, Boehringer Ingelheim International GmbH, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample